Business Insider6h
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...
Stocktwits on MSN1d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds
BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
ETF Daily News12h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
Seeking Alpha2d
BBIO BridgeBio Pharma, Inc.
View BridgeBio Pharma, Inc. (BBIO) current and estimated P/E ratio data provided by Seeking Alpha.
Investing1d
BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients BridgeBio Pharma, Inc. (Nasdaq: NASDAQ:BBIO) today shared positive results from the Japan ...
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
Why Was A.P. Bio Canceled Twice? Everything to Know About the Sitcom's History (And How Fans Brought It Back!) Before It Landed on Netflix
A.P. Bio' starring Glenn Howerton aired for two seasons on NBC and two seasons on Peacock. Here's everything to know about ...